Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient’s increased cancer risk, disease aggressiveness, optimize efficacy of chemotherapy and identify patients most suitable for therapy.



Hereditary Cancer




Myriad myRISK Hereditary Cancer is a gene panel for the identification of clinically significant mutations impacting inherited risks for eight important cancers. Blending genetic test status AND personal/family cancer history into clinically significant risk assessment and follow-up, the myRISK Hereditary Cancer test represents the next generation of cancer genetic testing.


Hereditary Breast and Ovarian Cancer




A predictive medicine product for hereditary breast and ovarian cancer.


BRACAnalysis® testing assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.


Hereditary Colorectal Cancer


A predictive medicine product for Lynch syndrome.


COLARIS® testing assesses a person’s risk of developinghereditary colorectal cancerand a woman’s risk of developinghereditary uterine/endometrialcancerby detecting disease-causing mutations in theMLH1, MSH2, MSH6, PMS2, EPCAMandMYHgenes.



A predictive medicine product for adenomatous polyposis colon cancer syndromes.


COLARIS AP® testing assesses a person’s risk of developinghereditary colorectal polypsand cancer by detecting mutations in the APC and MYH genes.


Prognostic gene expression panels in cancer: Prostate Cancer


A prognostic medicine product for prostate cancer.


Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris® can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness. The Prolaris® result provides 10-year risks for prostate cancer specific mortality in the biopsy setting or biochemical recurrence in the post-prostatectomy setting.


Prognostic gene expression panels in cancer: Breast Cancer


EndoPredict® is a multi-gene test for breast cancer patients.

EndoPredict® is a second generation gene expression analysis used to determine the risk of metastasis with endocrine therapy alone in patients with ER-positive HER2-negative primary breast cancer. Stratifying patients into clear High and Low Risk categories, EndoPredict® reliably predicts early and late metastases.


Companion Diagnostics – Ovarian Cancer

tumorbracana lysis

A companion diagnostic tumor test for ovarian cancer patients, to determine who may benefit from PARP inhibitor therapy.


Tumor BRACAnalysis CDx is a CE marked companion diagnostic tumor test for ovarian cancer patients. This test can detect up to 50% more patients with mutations in the BRCA1 and BRCA2 genes. BRCA mutation analysis is essential in ovarian cancer patients to identify the subset of women who are most likely to benefit from PARP inhibitors. 


Myriad Genetics also continues to offers the following products:


- MELARIS testing assesses a person's risk of developing hereditary melanoma by detecting inherited mutations in the p16 gene ( also called CDKN2A or INK4A) which is associated with hereditary melanoma and pancreatic cancer. Changes in the p16 gene increase cancer risk, making a melanoma diagnosis up to 50 times more likely by age 50.

For more information please visit: 


- PANEXIA is a genetic test specifically created to detect mutations in genes that result in an increased risk of pancreatic cancer, offering patients and their families insight into their risk of hereditary cancers. PANEXIA is a simple blood test that analyzes the PALB2 and BRCA2 genes, which are most commonly identified in families with hereditary pancreatic cancer. 

For more information please visit:  

Terms of Use

The following terms apply to the web site. The web site is owned and operated by Gene Analysis.


Contact info